Key Summary Points {#FPar1}
==================

**Why carry out this study?**Little information on possible local factors influencing response achievement and retention of plaque-type psoriasis to a 4-week course of treatment with calcipotriene plus betamethasone dipropionate aerosol foam is available.Correlations between baseline clinical/dermoscopic features of psoriatic plaques and therapeutic response as well as between residual dermoscopic findings in clinically improved/healed lesions at the end of treatment and post-treatment relapse were assessed.**What was learned from the study?**Poor therapeutic outcomes (no/limited response) were associated with lesions located on the legs, degree of baseline lesion infiltration and globular vessels on baseline dermoscopy, while dotted vessels on baseline dermoscopic examination were correlated with good outcomes (partial/optimal response).After a 4-week post-treatment follow-up, more than half of the lesions achieving improvement at the end of the therapy showed relapse, with a correlation between recurrence and persistence of vessels on dermoscopy at the end of the treatment.

Introduction {#Sec1}
============

Calcipotriene plus betamethasone dipropionate aerosol foam is an innovative topical treatment for plaque-type psoriasis which has been shown to be well-tolerated and significantly effective in terms of both objective improvement and itching/pain relief \[[@CR1]--[@CR4]\], with consequent relevant amelioration of patients' quality of life, which is often compromised in this condition \[[@CR5]\].

Whereas it has been demonstrated that the efficacy of such a treatment is independent of the patient's body mass index and disease extent/severity \[[@CR1], [@CR2]\], there is a lack of data regarding possible local (lesional) factors influencing therapeutic outcomes. In this regard, we recently showed that the therapeutic response of psoriatic patients to narrowband ultraviolet B (NB-UVB) phototherapy may be significantly influenced by the clinical features of each lesion, with plaques localized on the legs and/or showing more scaling/infiltration being associated to treatment resistance \[[@CR6]\]. Additionally, in the same study, we also demonstrated that dermoscopic assessment may highlight subclinical response predictors, with dotted and globular vessels related to good and bad outcomes, respectively \[[@CR5]\]. Similarly, Lallas et al. observed that the presence of purpuric dots on dermoscopy may be an early positive predictor of response in psoriatic patients treated with biologic agents \[[@CR7]\].

In addition to the possible role of dermoscopy to predict therapeutic response according to baseline features, such a technique might also have a potential role in assessing the likelihood of disease recurrence. Indeed, some lesions achieving complete clinical healing after treatment may still display residual subclinical abnormalities visible on dermoscopic examination (i.e. dotted/globular vessels) which might facilitate disease recurrence \[[@CR8]\].

In this prospective study, our aim was to assess possible correlations between baseline clinical/dermoscopic features of psoriatic plaques and therapeutic response, as well as between residual dermoscopic findings in clinically improved/healed lesions and post-treatment relapse, in order to better optimize the use of calcipotriene and betamethasone aerosol foam.

Methods {#Sec2}
=======

Adult patients (aged ≥ 18 years) suffering from moderate-to-severe plaque-type psoriasis (Psoriasis Area and Severity Index \[PASI\] score \> 10) for at least 6 months scheduled to undergo a 4-week (once-daily) treatment with calcipotriene plus betamethasone dipropionate aerosol foam were selected for this study (enrolment started in March 2019 and ended in November 2019). Patients currently taking anti-psoriatic treatments or those who had used systemic/topical anti-psoriatic drugs in the prior 12 weeks as well as subjects who had been exposed to sun during the previous 4 weeks were not considered to be eligible. We also excluded patients suffering from other relevant dermatoses, calcium metabolism disorders and severe kidney failure or liver dysfunction as well as pregnant or breastfeeding women.

Three target psoriatic plaques were randomly selected from each participant to be documented and followed. Lesions located on the scalp, face, folds and palmoplantar areas were not considered in the analysis. Anatomical localization of each plaque was identified by taking photographs and (when possible) recording distances from static benchmarks (e.g. bony prominences). Evaluations (both clinical and dermoscopic) were performed by two experienced researchers in consensus; in case of disagreement a third researcher was involved.

The study protocol involved three visits by the patients to the clinic, which is in line with our routine clinical practice in the management of patients with moderate-to-severe psoriasis undergoing calcipotriene plus betamethasone aerosol foam therapy: a baseline visit (T0), assessment at the end of therapy (week 4 \[T4\]) and a follow-up evaluation after 8 weeks from baseline (T8). Notably, between T4 and T8, patients were asked not to apply anything on the treated areas, with the exception of emollients. Patients requiring additional systemic/topical anti-psoriatic treatments during the whole study period were excluded from the analysis.

At the baseline (T0), each selected lesion was evaluated from a clinical and dermoscopic aspect. In the clinical evaluation, we calculated the Local Psoriasis Severity Index (LPSI), which corresponds to the sum of erythema, scaling/desquamation and induration/infiltration severity on a 5-point scale (0--4), with a total score ranging from 0 to 12. The dermoscopic analysis consisted of assessing the presence of several parameters that have been established in the literature as standardized criteria for the assessment of non-neoplastic dermatoses \[[@CR6], [@CR9]\]; these include dotted vessels (uniform, clustered, peripheral, reticular or unspecific distribution), globular vessels (uniform, clustered, peripheral, reticular or unspecific distribution), non-dotted/non-globular vessels (uniform, clustered, peripheral, reticular or unspecific distribution), white scales (diffusely distributed, patchily distributed, central or peripheral) and purple (haemorrhagic), white and brown areas (dots, globules, lines or structureless areas). Dermoscopic assessment was performed using a polarized hand-held device (10× magnification), with attention on minimizing the pressure in order to preserve vessel morphology and enhance visualization.

After 4 weeks of therapy (T4), we evaluated clinical improvement as limited response (LPSI improvement \< 50%), partial response (LPSI improvement of 50--75%) or optimal response (LPSI improvement \> 75%) and correlated the therapeutic outcome with initial clinical and dermoscopic features. We also performed a dermoscopic examination to assess subclinical changes of the lesions.

Finally, at week 8 (T8), we evaluated the change in the LPSI between week 4 and week 8 (ΔLPSI post-treatment) to assess the rate of post-treatment relapse (defined as the loss of at least 50% of LPSI amelioration reached at the end of treatment) in lesions achieving improvement (at least 50% compared to baseline) at T4. Additionally, we evaluated possible associations between relapse and (1) baseline clinical/dermoscopic features, (2) lesion localization and (3) dermoscopic findings at the end of the treatment (week 4).

Statistical Analysis {#Sec3}
--------------------

All analyses were performed using the SPSS version 20 software (IBM Corp., Armonk, NY, USA). Data are expressed as the mean ± standard deviation (SD) or as percentages. To assess the normality of the distribution we performed the Chi-square and Shapiro--Wilk tests; the Kruskal--Wallis and Mann--Whitney tests were used as non-parametric tests. All tests were two tailed, and *p* value of \< 0.05 was deemed to be statistically significant.

Compliance with Ethics Guidelines {#Sec4}
---------------------------------

The study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments and all the participants gave their informed consent to take part in the study and use personal records/photos for scientific purpose. Local ethical committee approval was obtained from the Comitato Etico Unico Regionale (C.E.U.R.) del Friuli Venezia Giulia (CEUR-2018-OS-140-ASUIUD).

Results {#Sec5}
=======

A total of 105 target lesions from 35 patients (16 females and 19 males; average age \[± SD\] 56 ± 16 years; average lesion duration 10 weeks) were included in the analysis. Most lesions were located on the trunk (43/105; 41%), legs (20/105; 19.1%) and extensor surfaces of the knees and elbows (18/105; 17.1%), whereas thighs and upper arms were involved in 7.6% (8/105) and 15.2% (16/105) of cases, respectively. Mean LPSI at baseline was 7.84 ± 1.3, with a mean score for erythema, scaling/desquamation and induration/infiltration of 2.6 ± 0.7 (for all such variables).

After 4 weeks of therapy, a total of 13 (12.4%) target lesions did not improve or reached only a limited response, while partial and optimal response were observed in 51 (48.6%) and 41 (39.0%) target lesions, respectively. A total of 32 lesions achieved a LPSI score of 0 or 1 (30.5%).

Notably, there was a significant correlation between anatomical localization and clinical response, with resistant (no or limited response) lesions more commonly located on the legs and extensor areas. In more detail, plaques located on the legs showed a 13-fold higher probability to show no/limited response than lesions located on the trunk or upper arms (odds ration \[OR\] 13.2, 95% confidence interval \[CI\] 2.8--63.8). No significant association was observed between clinical response and either baseline LPSI or baseline erythema/scaling, while a higher baseline infiltration score correlated with a poor therapeutic outcome (OR 3.9, 95% CI 1.3--11.9). Finally, no association was observed between clinical response and either lesion duration or gender. Analysis of the dermoscopic findings (Table [1](#Tab1){ref-type="table"}) revealed a significant correlation between the presence of globular vessels at baseline and no/limited response (OR 9, 95% CI 3.5--12.9) (Fig. [1](#Fig1){ref-type="fig"}). Interestingly, such vessels were more frequently observed in lesions on the legs than in those on other anatomical regions, while dotted vessels were more frequently present in lesions on the trunk (*p* \< 0.05). Moreover, considering only psoriatic plaques located on the legs, globular vessels were still significantly more common in non-responding lesions than in lesions achieving improvement (*p* \< 0.05). Finally, dotted vessels were associated with good outcomes (partial/optimal response) (OR 5.7, 95% CI 1.5--22.1) (Fig. [2](#Fig2){ref-type="fig"}).Table 1Analytical data on the baseline dermoscopic features of lesions included in the study grouped according to therapeutic responseDermoscopic featuresOptimal clinical response (LPSI improvement \> 75%) (*N* = 41 target lesions)Partial clinical response (LPSI improvement 50--75%) (*N* = 51 target lesions)No/limited clinical response (LPSI improvement \< 50%) (*N* = 13 target lesions)*N*%*N*%*N*%Dotted vessels^a^ Uniform2253.7917.6215.4 Clustered614.61223.517.7 Unspecific12.4815.7----Globular vessels^b^ Uniform49.8611.8215.4 Clustered37.359.8430.8 Unspecific12.423.9323.1Non-dotted/globular vessels Uniform24.9-------- Clustered----23.9---- Unspecific24.9713.717.7White scales Diffuse1741.52854.9430.8 Patchy1434.11733.3323.1 Central------------ Peripheral49.823.917.7Yellow scales Diffuse24.935.9323.1 Patchy37.312.0215.4 Central------------Peripheral12.4--------Haemorrhagic spots512.21529.4646.2Hypopigmented areas24.9713.717.7Pigmentation structures (brown network, brown dots/globules, and brown structure-less areas)------------Values in table are presented as the number of target lesions with a specific demoscopic feature, with the percentage in parenthesis*LPSI* Local Psoriasis Severity Index^a^A significant correlation between dotted vessels at baseline and good therapeutic outcomes (partial/optimal response) was found (odds ratio 5.7, 95% confidence interval 1.5--22.1)^b^A significant correlation between globular vessels and poor therapeutic outcomes (no/limited response) was found (odds ratio 9, 95% confidence interval 3.5--12.9)Fig. 1**a**,**b** Clinical picture of a target psoriatic plaque on the right leg (white square) at baseline (**a**), with corresponding dermoscopy image showing presence of uniform globular vessels (better visible in inset) and diffuse white scaling (**b**).**c** Clinical aspect of the same lesion after 4 weeks of therapy with calcipotriene plus betamethasone dipropionate aerosol foam showing limited improvement (Local Psoriasis Severity Index improvement of \< 50%)Fig. 2**a**,**b** Clinical picture of a target psoriasis plaque (white square) at baseline (**a**), with corresponding dermoscopy image showing presence of uniform dotted vessels (better visible in inset) (**b**).**c**,**d** After 4 weeks of therapy with calcipotriene plus betamethasone dipropionate aerosol foam the target lesion (white square) showed complete clinical healing (**c**), but vessels were still evident on dermoscopy (better visible in inset) (**d**).**e** Clinical recurrence of the lesion (white square) after 4 weeks of post-treatment follow-up (T8)

After a 4-week post-treatment follow-up, 58.7% (54/92) of the lesions showed relapse. A similar (no statistical difference) relapse rate was observed when only lesions reaching complete/nearly complete clinical improvement (LPSI 0 or 1) at T4 were considered (50%; 16/32). No correlation between response retention and either lesion localization or baseline LPSI was observed. Similarly, response retention was not affected by baseline erythema, scaling/desquamation, induration/infiltration or baseline dermoscopic features. On the other hand, a statistically significant association was found between relapse and persistence of vessels at the end of the therapy when considering both all the lesions regardless of degree of improvement at T4 (OR 17.3 CI 95% 6.0--49.7) and only lesions reaching a complete/nearly complete clinical healing (LPSI 0 or 1) at T4 (OR 21.0 CI95% 3.3--135.5) (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}).Fig. 3**a**--**c** Clinical pictures of a target psoriatic plaque on the abdomen (white square) at baseline (**a**) and after 4 weeks of treatment with calcipotriene plus betamethasone dipropionate aerosol foam with complete healing (white square) based on both clinical (**b**) and dermoscopy (absence of vessels) (**c**) findings.**d** No recurrence was evident after 4 weeks of post-treatment follow-up

Discussion {#Sec6}
==========

Most of the studies published to date that have evaluated the efficacy of calcipotriene plus betamethasone dipropionate aerosol foam for the treatment of plaque-type psoriasis have focused on general disease improvement without any assessment of local (lesional) outcomes. The consequence has been a lack of data on the effects of this therapy on specific target lesions and possible local factors that may influence therapeutic response. Only one prospective study has specifically evaluated the efficacy of calcipotriene plus betamethasone dipropionate aerosol foam on target lesions, with the results showing a significant improvement of local outcomes in the analysed plaques \[[@CR10]\]. Our study further confirms the "local" efficacy of this therapy, although we also observed a small subgroup (12.4%) of lesions that either did not improve or achieved only a limited response. One possible explanation for this difference may be that only plaques on the elbows and knees were included in the previous study \[[@CR10]\]. Indeed, our analysis showed that resistant lesions were mainly located on the legs, thereby supporting the hypothesis that anatomical localization may affect clinical response. On the other hand, we did not find a correlation between therapeutic response and other clinical variables, apart from the infiltration degree of the lesions, with thicker plaques showing poor outcomes.

The negative impact of the localizion of lesions on legs and high lesion infiltration degree on therapeutic efficacy is consistent with the results from Errichetti and Stinco's (two of the authors of the present invesigation) study on psoriatic patients treated with NB-UVB \[[@CR6]\]. However, differently from our previous study, we did not observe any association between lesion scaling degree and poor response to calcipotriene plus betamethasone dipropionate aerosol foam, likely due the high penetration of the treatment through the corneum layer \[[@CR11]\].

While the association between lesion infiltration and reduced response is easily explained by the physical barrier of the plaque to drug penetration, the actual mechanisms underlying the correlation between the lesion localization on legs and poor therapeutic outcomes is yet to be completely understood, although vascular factors has been speculated to be involved \[[@CR6]\]. Indeed, as observed in the present study and our previous analysis \[[@CR6]\], psoriatic plaques localized on the legs more commonly feature vessels of a larger size on dermoscopy (i.e. globular vessels), particularly those lesions showing limited/no clinical response, thereby indicating a possible association between vascular dilation/increased vascular flow and therapeutic resistance in this anatomical region \[[@CR6]\]. This speculation is further supported by the different response rate to calcipotriene plus betamethasone dipropionate aerosol foam according to vessel size observed on dermoscopy, with the presence of globular vessels associated with poor (limited/no response) outcomes.

In line with the hypothesis for psoriatic patients treated with NB-UVB previously proposed by Errichietti and Stinco \[[@CR6]\], it is possible to speculate that the correlation between the therapeutic resistance of psoriatic plaques to calcipotriene plus betamethasone dipropionate aerosol foam and lesion localization on legs might be the result of a higher inflammatory activity related to a greater hydrostatic pressure in a subset of patients with microcirculation impairment/vessel dilation, with globular vessels potentially being a dermoscopic marker of higher hydrostatic pressure and, consequently, poor outcome. Accordingly, a higher hydrostatic pressure would lead to increased vessel permeability, with the consequent formation of a fibrin cuff around dermal capillaries that would cause tissue hypoxia, cell damage and the release of inflammatory mediators, which may in turn be responsible for treatment resistance \[[@CR12]--[@CR14]\]. However, it is also possible that the different pattern of vascularization (dotted vs. globular vessels) and the resulting response might be due to different cytokine milieus; to date, no specific evidence on this possibility is available in the literature, thus preventing us from further speculation in this regard. Future research is therefore needed to address this notion.

In the post-treatment analysis, we observed a significant tendency for relapse in the 4 weeks after a course of calcipotriol plus betamethasone dipropionate spray foam, with more than half of the lesions that had achieved improvement at the end of the therapy experiencing a loss of response. Importantly, relapse was strongly associated with the persistence of vascular structures on dermoscopy at the end of the therapy. This was observed in all of the lesions regardless the degree of improvement but also when only lesions reaching a complete/nearly complete clinical healing at the end of the treatment were considered, with a risk of disease recurrence in the case of vessel persistence after the treatment being 17- and 21-fold higher, respectively.

A possible role of persistence of vascular changes in promoting disease relapse is supported by two well-known factors: (1) the onset of dermal microangiopathy in psoriasis usually precedes clinical relapse and (2) treatments favouring microangiopathy regression lead to a more stable clinical healing \[[@CR15], [@CR16]\]. In such a scenario, it would be advisable to achieve a "dermoscopic healing", rather than a mere "clinical remission", to ensure a longer response retention. In our personal experience based on every other day assessment of two volunteers not included in this study and who displayed vessels persistence at the end of a standard 4-week treatment with calcipotriol plus betamethasone dipropionate spray foam despite clinical healing, we found that vessels disappearance occurred after 6 and 8 days, respectively, of "extra" application. However, specific systematic studies are needed to precisely understand how long the drug should be used to achieve dermoscopic vascular normalization.

Conclusions {#Sec7}
===========

The results of our study confirm that calcipotriol/betamethasone dipropionate spray foam is an effective treatment for plaque-type psoriasis, although clinical response can be adversely affected by local factors, including severe baseline infiltration and distribution of lesions on legs. We also found that the presence of globular vessels at baseline on dermoscopy is a negative response predictor as the presence of this type of vessel was significantly more frequent in non-responding lesions.

Interestingly, a significant tendency of the lesions to relapse in the 4 weeks after a standard course of calcipotriol plus betamethasone dipropionate spray foam was observed in this study. However, according to our findings, it would appear that disease recurrence is significantly associated to vessels persistence on dermoscopy at the end of the treatment, thereby suggesting that therapy should be continued until complete "dermoscopic healing" in order to optimize the treatment and achieve a longer remission.
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